

**Supplemental Information**

**Long Noncoding RNA OIP5-AS1 Promotes the  
Progression of Liver Hepatocellular Carcinoma  
via Regulating the hsa-miR-26a-3p/EPHA2 Axis**

**Yu-Shui Ma, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Xu-Chao Zhu, Ji-Bin Liu, Fei Yu, Zhi-Zhen Li, Jing-Han Wang, Qing-Xiang Gao, Bin Yi, Hui-Min Wang, Li-Peng Gu, Liu Li, Lin-Lin Tian, Yi Shi, Xiao-Qing Jiang, Da Fu, and Xiong-Wen Zhang**

1 **Supplemental Information**

2


3 **Long noncoding RNA OIP5-AS1 promotes the progression of liver**  
4 **hepatocellular carcinoma via regulating hsa-miR-26a-3p/EPHA2 axis**

5

6 Supplemental information contains three supplemental figures and legends.

7

8 **Supplementary figure and legend**



9

10 **Supplementary Figure 1. Identification of significantly dysregulated**

11 **lncRNAs in LIHC.** (A) Hierarchical clustering of significantly dysregulated


12 lncRNAs in LIHC was performed using the multiple experiment viewer 4.7.1

13 software programs. (B-D) The Kaplan-Meier method was used to evaluate the

14 relationship between lncRNA CRNDE (B), OIP5-AS1 (C) and ZEB1-AS1 (D)

15 expression and overall survival of 371 LIHC patients from TCGA datasets.

16




17

18 **Supplementary Figure 2. The expression of OIP5-AS1 in LIHC samples.**

19 (A-C) The expression level of CRNDE (A), OIP5-AS1 (B) and ZEB1-AS1 (C) in  
 20 371 LIHC tissues and 50 adjacent noncancerous tissues. (D-F) The correlation  
 21 of CRNDE (D), OIP5-AS1 (E) and ZEB1-AS1 (F) in 371 LIHC tissues and 50  
 22 adjacent noncancerous tissues. (G) OIP5-AS1 expression level was examined  
 23 in GSE104310 dataset. (H) OIP5-AS1 expression level was examined in  
 24 GSE84005 dataset. (I) The correlation of OIP5-AS1 expression level and  
 25 tumor stage in 371 LIHC patients.

26



27

28 **Supplementary Figure 3. The expression and prognostic value of**

29 **hsa-miR-26a-3p and in LIHC samples. (A)** The expression level of  
30 hsa-miR-26a-3p in 371 LIHC tissues and 50 adjacent noncancerous tissues.

31 (B, C) The expression level (B) and correlation (C) of hsa-miR-26a-3p in 50  
32 pairs of LIHC tissues and adjacent noncancerous tissues. (D) The correlation  
33 of hsa-miR-26a-3p expression level and tumor stage in 371 LIHC patients.

34 The Kaplan-Meier method was used to evaluate the relationship between  
35 hsa-miR-26a-3p expression and overall survival of 371 LIHC patients. (F) The  
36 Kaplan-Meier method was used to evaluate the relationship between

37 OIP5-AS1/hsa-miR-26a-3p expression and overall survival of 371 LIHC

38 patients. H/L, high OIP5-AS1 and low hsa-miR-26a-3p expression; L/H, low  
39 OIP5-AS1 and high hsa-miR-26a-3p expression. (G, H) The correlation  
40 between hsa-miR-26a-3p and OIP5-AS1 in 50 adjacent noncancerous tissues  
41 (H) and 371 LIHC tissues (G). (I) Hsa-miR-26a-3p expression level was  
42 examined in GSE21362 dataset. (J) Hsa-miR-26a-3p expression level was  
43 examined in GSE36915 dataset. (K) Hsa-miR-26a-3p expression level in 241  
44 adjacent noncancerous tissues, 180 non-metastatic and 60 metastatic LIHC  
45 tissues from GSE6857 dataset. (L) Hsa-miR-26a-3p expression level in 178  
46 alive and 59 dead LIHC patients from GSE6857 dataset.